BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26844496)

  • 1. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection.
    Chen JL; Lao XM; Lin XJ; Xu L; Cui BK; Wang J; Lin GH; Shuang ZY; Mao YZ; Huang X; Yun JP; Jin JT; Li SP
    Medicine (Baltimore); 2016 Feb; 95(5):e2665. PubMed ID: 26844496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
    Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
    Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
    Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
    Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
    Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
    Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
    Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
    BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.
    Huang ZM; Li W; Li S; Gao F; Zhou QM; Wu FM; He N; Pan CC; Xia JC; Wu PH; Zhao M
    J Immunother; 2013 Jun; 36(5):287-93. PubMed ID: 23719239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Cancer Immunol Immunother; 2019 Jan; 68(1):23-32. PubMed ID: 30232520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant cytokine-induced killer cells with minimally invasive therapies augmented therapeutic efficacy of unresectable hepatocellular carcinoma.
    Huang ZM; Lai CX; Zuo MX; An C; Wang XC; Huang JH; Ning E
    J Cancer Res Ther; 2020; 16(7):1603-1610. PubMed ID: 33565506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.
    Chen ZH; Zhang XP; Zhou TF; Wang K; Wang H; Chai ZT; Shi J; Guo WX; Cheng SQ
    Eur J Surg Oncol; 2019 Nov; 45(11):2188-2196. PubMed ID: 31256949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria.
    Hou YF; Li B; Wei YG; Yang JY; Wen TF; Xu MQ; Yan LV; Chen KF
    Medicine (Baltimore); 2015 Dec; 94(48):e2070. PubMed ID: 26632890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
    Hui D; Qiang L; Jian W; Ti Z; Da-Lu K
    Dig Liver Dis; 2009 Jan; 41(1):36-41. PubMed ID: 18818130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study.
    Wang L; Wang W; Rong W; Li Z; Wu F; Liu Y; Zheng Y; Zhang K; Siqin T; Liu M; Chen B; Wu J
    BMC Cancer; 2020 Jul; 20(1):614. PubMed ID: 32611327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma: A retrospective cohort study.
    Liu J; Zhu Q; Li Y; Qiao GL; Xu C; Guo DL; Tang J; Duan R
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):330-338. PubMed ID: 29551612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study.
    Han J; Li ZL; Xing H; Wu H; Zhu P; Lau WY; Zhou YH; Gu WM; Wang H; Chen TH; Zeng YY; Wu MC; Shen F; Yang T
    HPB (Oxford); 2019 Aug; 21(8):962-971. PubMed ID: 30718183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review.
    Cai XR; Li X; Lin JX; Wang TT; Dong M; Chen ZH; Jia CC; Hong YF; Lin Q; Wu XY
    Oncotarget; 2017 May; 8(19):31318-31328. PubMed ID: 28412743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.
    Wei W; Jian PE; Li SH; Guo ZX; Zhang YF; Ling YH; Lin XJ; Xu L; Shi M; Zheng L; Chen MS; Guo RP
    Cancer Commun (Lond); 2018 Oct; 38(1):61. PubMed ID: 30305149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
    Pan QZ; Wang QJ; Dan JQ; Pan K; Li YQ; Zhang YJ; Zhao JJ; Weng DS; Tang Y; Huang LX; He J; Chen SP; Ke ML; Chen MS; Wicha MS; Chang AE; Zeng YX; Li Q; Xia JC
    Sci Rep; 2015 Mar; 5():9202. PubMed ID: 25776856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis.
    Chen ZH; Zhang XP; Wang H; Chai ZT; Sun JX; Guo WX; Shi J; Cheng SQ
    HPB (Oxford); 2019 Aug; 21(8):935-944. PubMed ID: 30871805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.